TY - JOUR
T1 - Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors
AU - Liang, Xiuming
AU - Gupta, Dhanu
AU - Xie, Junhua
AU - Van Wonterghem, Elien
AU - Van Hoecke, Lien
AU - Hean, Justin
AU - Niu, Zheyu
AU - Ghaeidamini, Marziyeh
AU - Wiklander, Oscar P.B.
AU - Zheng, Wenyi
AU - Wiklander, Rim Jawad
AU - He, Rui
AU - Mamand, Doste R.
AU - Bost, Jeremy
AU - Zhou, Guannan
AU - Zhou, Houze
AU - Roudi, Samantha
AU - Estupiñán, H. Yesid
AU - Rädler, Julia
AU - Zickler, Antje M.
AU - Görgens, André
AU - Hou, Vicky W.Q.
AU - Slovak, Radka
AU - Hagey, Daniel W.
AU - de Jong, Olivier G.
AU - Uy, Aileen Geobee
AU - Zong, Yuanyuan
AU - Mäger, Imre
AU - Perez, Carla Martin
AU - Roberts, Thomas C.
AU - Carter, Dave
AU - Vader, Pieter
AU - Esbjörner, Elin K.
AU - de Fougerolles, Antonin
AU - Wood, Matthew J.A.
AU - Vandenbroucke, Roosmarijn E.
AU - Nordin, Joel Z.
AU - EL Andaloussi, Samir
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/4/29
Y1 - 2025/4/29
N2 - Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we develop highly potent engineered extracellular vesicles (EVs) by incorporating bio-inspired attributes required for effective delivery. These comprise an engineered mini-intein protein with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein for endosomal escape. Combining these components allows high efficiency recombination and genome editing in vitro following EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, infusion of a single dose Cre loaded EVs into the lateral ventricle in brain of Cre-LoxP R26-LSL-tdTomato reporter mice results in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.
AB - Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we develop highly potent engineered extracellular vesicles (EVs) by incorporating bio-inspired attributes required for effective delivery. These comprise an engineered mini-intein protein with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein for endosomal escape. Combining these components allows high efficiency recombination and genome editing in vitro following EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, infusion of a single dose Cre loaded EVs into the lateral ventricle in brain of Cre-LoxP R26-LSL-tdTomato reporter mice results in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.
UR - http://www.scopus.com/inward/record.url?scp=105003868837&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-59377-y
DO - 10.1038/s41467-025-59377-y
M3 - Article
C2 - 40301355
AN - SCOPUS:105003868837
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4028
ER -